About 50 years ago, when I was a Section Chief at the National Institute of Mental Health working on biogenic amines, I received a call from Dr. John Burns recommending a brilliant young researcher, Louis Lemberger, to come to my laboratory as a Research Associate to continue his work on drug metabolism. This was during the Vietnam War and a position in the US Public Health Service as a Commissioned Officer and time spent at NIH would satisfy his obligation for Military Service. It was a very propitious time: Rapheal Mechoulam had recently discovered Δ9-tetrahydrocannabinol (THC) as the active component of marihuana, Julie Axelrod had just received the Nobel Prize, radioactively labeled substances were readily available, and interest in psychoactive drugs was high. Lou made most of the opportunity, and during the 2 years he spent at NIH, he published about a dozen papers, many as first author of studies on the metabolism, pharmokinetics, and effects of THC in humans and animals.
His productivity before and during his time at NIH was a springboard from which he ascended to prominence in the pharmaceutical industry and as an International leader in the fields of pharmacology, clinical pharmacology, experimental biology, and drug development. Lou was an ardent basketball and football fan even in the early days at NIH, and with his naturally acquired interpersonal relationship skills led him into long-term friendships with a host of professional and other friends. It was indeed a special pleasure to have had him in our laboratory and to follow his many accomplishments over these many years.
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